Duodenal mucosal intervention in the management of MASLD and type 2 diabetes
Open Access
- 14 January 2026
- journal article
- review article
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 18 (1)
Abstract
The pathophysiology of metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2DM) is rooted in the gut-liver axisKeywords
This publication has 18 references indexed in Scilit:
- Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled TrialsMetabolites, 2021
- Minireview: Current status of endoscopic duodenal mucosal resurfacingObesity Research & Clinical Practice, 2020
- A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statementJournal of Hepatology, 2020
- Nonalcoholic Fatty Liver Disease 2020: The State of the DiseaseGastroenterology, 2020
- Endoscopic duodenal mucosal resurfacing improves glycaemic and hepatic indices in type 2 diabetes: 6-month multicentre resultsJHEP Reports, 2019
- The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysisJournal of Hepatology, 2019
- Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes mellitus: one year results from the first international, open-label, prospective, multicentre studyGut, 2019
- The Duodenum harbors a Broad Untapped Therapeutic PotentialGastroenterology, 2018
- Endoscopic Duodenal Mucosal Resurfacing for the Treatment of Type 2 Diabetes: 6-Month Interim Analysis From the First-in-Human Proof-of-Concept StudyDiabetes Care, 2016
- Effect of Bariatric Surgery on Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-AnalysisClinical Gastroenterology and Hepatology, 2008